A novel sublingual vaccine for preventing andtreating periodontitis
Active Grant Awarded
- Award ID
- R43DE036133
- Recipient
-
Virtici LLC UEI V29SWGG4MQ64
- Awarding agency
-
National Institute of Dental and Craniofacial Research
National Institutes of Health, Department of Health and Human Services
- Obligated
- $306,464
Award facts
- Assistance listing
- 93.121 Oral Diseases and Disorders Research
- Completion date 10% complete
- Place of performance
- Seattle, WA 98122, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Institute of Dental and Craniofacial Research, awarded Virtici LLC a grant of $306,464 on September 14, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121). The award funds development of a novel sublingual vaccine for preventing and treating bacterial-induced periodontitis, targeting the oral pathogens Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola. The source states the vaccine should be safe, targeted to those three pathogens while preserving a healthy oral microbiome, thermostable for global distribution, and orally administered. The program supports basic, translational, and clinical dental, oral, and craniofacial research through grants and cooperative agreements. The award obligates $306,464, with performance in Seattle, WA 98122 and an ultimate completion date of August 31, 2028.
Description
- Abstract
- Our goal is to develop a novel sublingual (SL) vaccine for the treatment and prevention of bacterial-induced periodontitis. Oral infection by the key pathogens porphyromonas gingivalis (PG), tannerella forsythia (TF), and treponema denticola (TD) leads to inflammation and bleeding of the gums, called gingivitis, and eventually bone and tooth loss, called PERIODONTITIS1-4. Almost 50% of adults worldwide over the age of 30 have periodontal disease, making IT one of the most common infections in HUMANS5 6, 7. Periodontal infection is closely associated with several other chronic health conditions, including alzheimer's disease, cardiovascular disease, cancer and ARTHRITIS8-14. Thus, the economic burden of periodontitis is substantial, with aggregate costs in the U.S. Estimated at $3.49 billion in direct costs and $150.57 billion in indirect costs as of 201815. Currently available treatments rely on dental cleaning procedures and antiseptic mouth rinses, or in severe cases, antibiotics or SURGERY16. These approaches have varied success, are nonspecific, and can result in disruption of the natural oral microbiome. Dental procedures are costly, time consuming, and not preventative. The use of antibiotics and antiseptic mouthwashes is typically short-term and may have side effects such as tartar buildup, tooth staining, and mouth sores. Moreover, the use of antibiotics and antiseptics disrupts and destroys the normal healthy oral microbiome, which acts as a barrier to colonization by pathogenic bacteria. Ideally, any SL vaccine developed today for the treatment of periodontitis should be safe (no side effects), targeted (prevent PG, TF, and TD infection, preserve a healthy microbiome), thermostable (for global distribution), and orally administered (for easy, rapid vaccination). No vaccine currently exists that meets these criteria, and no drug currently in use or in development for the treatment of bacterial-induced periodontitis meet all these criteria. Our objective is to develop a first-in-class, SL PG-TF-TD vaccine, called SG3, for the treatment and prevention of bacterial-induced periodontal disease. The key objectives of this proposal are to: 1) determine the optimal formulation of the SG3 SL vaccine, 2) demonstrate that our SG3 sublingual vaccine stimulates robust mucosal immunity, and 3) show that SG3 significantly reduces periodontitis in mice. Completion of this application will also establish an SL vaccine platform that can be leveraged to develop SL vaccines against other pathogens that generate robust mucosal immunity, can be administered easily and pain-free, and are thermostable for rapid, global distribution.
Quick answers
Who received award R43DE036133?
R43DE036133 was awarded to Virtici LLC by National Institute of Dental and Craniofacial Research (National Institutes of Health) on September 14, 2026.
How much is award R43DE036133 worth?
$306,464 has been obligated on R43DE036133.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award